- Paclitaxel/carboplatin/etoposide versus gemcitabine/irinotecan in the first-line treatment of patients with carcinoma of unknown primary site: a randomized, phase III Sarah Cannon Oncology Research Consortium Trial. Hainsworth, J.D., Spigel, D.R., Clark, B.L., Shipley, D., Thompson, D.S., Farley, C., West-Osterfield, K., Lane, C.M., Cescon, T., Bury, M.J., Greco, F.A. Cancer. J (2010)